BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35137422)

  • 1. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
    Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
    Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
    Choi H; Seo GH
    J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
    Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
    J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
    Ha Y; Chon YE; Kim MN; Lee JH; Hwang SG
    Sci Rep; 2020 Aug; 10(1):13537. PubMed ID: 32782369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
    J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
    J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
    Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study.
    Kim DG; Choi Y; Rhu J; Hwang S; You YK; Kim DS; Nah YW; Kim BW; Cho JY; Kang KJ; Yang JD; Choi D; Joo DJ; Kim MS; Ryu JH; Lee JG;
    Liver Transpl; 2023 Dec; 29(12):1272-1281. PubMed ID: 37489922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
    Hsu YC; Wong GL; Chen CH; Peng CY; Yeh ML; Cheung KS; Toyoda H; Huang CF; Trinh H; Xie Q; Enomoto M; Liu L; Yasuda S; Tanaka Y; Kozuka R; Tsai PC; Huang YT; Wong C; Huang R; Jang TY; Hoang J; Yang HI; Li J; Lee DH; Takahashi H; Zhang JQ; Ogawa E; Zhao C; Liu C; Furusyo N; Eguchi Y; Wong C; Wu C; Kumada T; Yuen MF; Yu ML; Nguyen MH
    Am J Gastroenterol; 2020 Feb; 115(2):271-280. PubMed ID: 31634265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Choi J; Jo C; Lim YS
    Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
    Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis.
    Jeong S; Cho Y; Park SM; Kim W
    J Clin Gastroenterol; 2021 Oct; 55(9):e77-e86. PubMed ID: 33883516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
    Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
    Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
    Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
    Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.